Stellar is a clinical study for retinitis pigmentosa and Usher syndrome. This page provides patients, their families and care givers with information about the trial and trial participation.

What is Stellar?

What is Stellar?

Stellar is the name of a clinical trial that aims to study whether the investigational RNA therapy QR-421a is effective and safe for people with retinitis pigmentosa and Usher syndrome due to mutations in exon 13 of the USH2A gene. This Phase 1/2 trial is the first clinical study to investigate QR-421a. If you are interested in joining this trial, please read about the eligibility criteria.

For the Stellar study, we teamed up with the Foundation Fighting Blindness. In the partnership, the foundation supports the trial financially and provides learnings from the “RUSH2A” natural history study they are conducting.

Stellar clinical trial logo
What is QR-421a?

What is QR-421a?

QR-421a is an investigational RNA therapy that aims to stop vision loss or restore vision in people that have retinitis pigmentosa due to a mutation in exon 13 of the USH2A gene.

Ophthalmologist doing eye measurements
How is the trial set up?

How is the Stellar trial set up?

Clinical trials are used by researchers to find out whether new medicines are effective and safe. Key aspects of the Stellar trial are the following:

  • Stellar aims to find out whether QR-421a is safe and well-tolerated, and whether it is effective at stabilizing or improving vision;
  • The study will enroll adults (age 18 and up);
  • Study participants will be divided into three groups.
    Group 1: will receive a single intravitreal injection (injection into the eye) with dose 1 of QR-421a or a sham procedure (intravitreal injection is mimicked but no injection and no study medicine is given).
    Group 2: will receive a single intravitreal injection with dose 2 of QR-421a or a sham procedure.
    Group 3: will receive a single intravitreal injection with dose 3 of QR-421a.
Is Stellar for me?

Is Stellar for me?

The information below outlines the main criteria for participation in the trial. Participants must:

  • Have an established genetic diagnosis of Usher syndrome or RP caused by mutations in exon 13 of the USH2A gene;
  • Be 18 years of age or older;
  • Not participate in another clinical study during the Stellar trial.

Unfortunately not everyone who is eligible and interested may be able to participate. Please sign up for the Eye Connect newsletter or follow us on social media if you would like to stay informed on our progress and future trials.

Clinical trial participation

How to participate in the clinical trial?

We recommend that you discuss your situation and suitability for the trial with your doctor. They will be able to refer you to a medical center where the Stellar trial is conducted. You can also contact the trial center directly.

Stellar is currently open at the following locations in the United States, Canada, and Europe.

  • Center for Clinical Research Operations, Massachusetts Eye and Ear 

    Boston, Massachusetts, United States, 02114
    Contact: 617-573-6060   OphthalmologyClinicalResearch@meei.harvard.edu

    University of Michigan, Kellogg Eye Center

    Ann Arbor, Michigan, United States, 48105
    Contact: Callie Gordon | 734-615-8560
    callieg@med.umich.edu

    Casey Eye Institute, Oregon Health & Science University

    Portland, Oregon, United States, 97239
    Contact: Connor Benson | 503-494-9501
    bensoco@ohsu.edu   

    Retina Foundation of the Southwest

    Dallas, Texas, United States, 75231
    Contact: Martin Klein | 214-363-3911 ext 116   mklein@retinafoundation.org   

  • UZ Gent, Department Ophthalmology

    Gent, Belgium, 9000
    Contact: Bart Leroy, Prof Dr | +32 (9) 332 5342
    Bart.Leroy@UGent.be

  • Centre for Innovative Medicine, Department of Paediatric Surgery, Montreal Children's Hospital at the McGill University Health Centre

    Montréal, Canada, H4A 3J1
    Contact: Elvis Atanga | 514 412 4400 ext 22891
    cim.ecr@muhc.mcgill.ca
    Principal Investigator: Robert Koenekoop, MD, PhD

  • Hôpital Gui de Chauliac - CHRU de Montpellier - Maladies Sensorielles Génétique

    Montpellier, France, 34295
    Contact: Nathalie Meunier | +33 (0) 7880 14358 
    n-meunier@chu-montpellier.fr

    Centre de maladies rares CHNO des Quinze Vingts

    Paris, France, 75012
    Contact: Céline Devisme | +33 1 40 02 14 57
    cdevisme@15-20.fr

The above information is also available on worldwide clinical trial database clinicaltrials.gov with identifier (NCT number): NCT03780257.

What is retinitis pigmentosa?

What is USH2A mediated retinitis pigmentosa?

Retinitis pigmentosa (RP) is an inherited retinal disease that leads to vision loss and blindness. Symptoms usually start with night blindness during childhood and further progress with loss of side (peripheral) vision leading to tunnel vision. Loss of central vision appears during adulthood and blindness is frequent in adulthood.

The vision loss can exist in combination with hearing loss, this disease is called Usher syndrome. Usher syndrome is the leading cause of combined deafness and blindness. 

RP is a genetic disease that causes a mistake, or mutation, in the patient’s RNA. Because of the mutation, an essential protein in the eye is not produced or cannot function, and this leads to the deterioration of the light detecting cells in the retina. Both Usher syndrome and RP can be caused by mutations in the USH2A gene and often these mutations appear in a specific part, called exon 13. Because of the mutation, the USH2A RNA cannot produce a functional Usherin protein that plays a role in the development of both the ear and eye. 

In the Western world, up to 16,000 people have vision loss due to mutations in exon 13 of the USH2A gene. To date, there are no other therapies approved or in clinical development that treat the vision loss associated with USH2A exon 13 mutations.

What are mutations in exon 13?

What are mutations in exon 13 of the USH2A gene?

Every gene is made up of multiple parts called exons that together contain the information to build one specific protein. The USH2A gene has 72 exons that together code for the Usherin protein. Many RP-causing mutations are known to occur in one particular part, exon 13, of the USH2A gene. Below we have listed mutations in exon 13 that are known to cause RP.

RP-causing mutations in USH2A exon 13

Mutation

DNA format

Protein format

1

c.2209C>T

p.(Arg737*)

2

c.2242C>T

p.(Gln748*)

3

c.2276G>T

p.(Cys759Phe)

4

c.2299delG

p.(Glu767Serfs*21)

5

c.2332G>T

p.(Asp778Tyr)

6

c.2391_2392del

p.(Cys797*)

7

c.2414G>C

p.(Gly805Ala)

8

c.2431A>T

p.(Lys811*)

9

c.2431_2432del

p.(Lys811Aspfs*11)

10

c.2440C>T

p.(Gln814*)

11

c.2445C>A

p.(Cys815*)

12

c.2525dup

p.(Leu843Profs*8)

13

c.2541C>A

p.(Cys847*)

14

c.2551A>T

p.(Lys851*)

15

c.2610C>A

p.(Cys870*)

16

c.2653C>T

p.(His885Tyr)

17

c.2755C>T

p.(Gln919*)

18

c.2761del

p.(Leu921Cysfs*46)

19

c.2776C>T

p.(Arg926Cys)

20

c.2797C>T

p.(Gln933*)

21

c.2802T>G

p.(Cys934Trp)

22

c.2802 T>G

p.(Cys934Trp)

Source: databases.lovd.nl. As new mutations are being discovered in ongoing research this list may not be complete. For each mutation both the DNA and protein formats are given because genetic test results may provide both or one of the formats. Explanation of codes: ‘c.’ stands for complementary DNA, the number gives the position in the gene, the letters explain what has changed, for example 2209C>T means the C at position 2209 was changed into a T and 2299delG means that the G at position 2299 was deleted from the gene. ‘p’ stands for protein, the letters and numbers explain what amino acid (building block of a protein) was changed, for example Arg737 means the amino acid arginine at position 737 changed. ‘*’ means protein production is stopped at that position and Cys759Phe means the cysteine at position 759 changed into a phenylalanine.

FAQ

Frequently asked questions

Below you will find answers to the most frequent questions about the Stellar trial.

  • Intravitreal injection is one of the most commonly performed procedures for eye diseases. The inside of the eye is filled with a jelly-like fluid (vitreous). During an intravitreal injection, the eye doctor will inject medicine into the vitreous with a very small needle, after numbing the eye. The patient may feel some pressure but no pain. Learn more about intravitreal injection.

  • An RNA therapy is designed to correct the mistake, or mutation, in the RNA of someone with a genetic disease. By correcting the mistake, the RNA can then be used to create the protein that the cell needs, taking away the underlying cause of the disease.

    Learn more about how RNA therapy works.

  • Yes, travel and accommodation costs will be covered.

  • While available information on QR-421a is encouraging, there is still much to learn about QR-421a and its effects. Therefore, QR-421a is currently not available outside clinical trials.

  • People participate in clinical trials for different reasons. Some participate because they want to learn more about their disease. Others participate because they want to help with the development of new treatments that could help them and others in the future. 

    If you take part in a clinical trial, you may be one of the first people to benefit from new study medication. Clinical trials follow a specific set of standards and are strictly regulated to help keep all participants safe. All clinical trials are reviewed and approved by a committee of independent experts (Ethics Committee or Institutional Review Board). 

    During a clinical trial, participants are carefully monitored. In addition to eye tests, general safety tests may be performed during study visits, such as blood tests, blood pressure, heart rate and temperature. 

    Learn more about clinical trials.

Ask a question

If you have any questions, please contact us using the form below. You can also mail directly to patientinfo@proqr.com.